CLARITY-AD (NCT03887455) was a landmark Phase 3 randomized, double-blind, placebo-controlled trial evaluating lecanemab (Leqembi) in early Alzheimer's disease patients. The trial met its primary endpoint, demonstrating statistically significant slowing of cognitive decline and represents the first Phase 3 trial of an anti-amyloid antibody to show clear clinical benefit in early AD[1].
Lecanemab received accelerated approval from the FDA in January 2023 based on the CLARITY-AD results, making it the first amyloid-targeting therapy to demonstrate meaningful clinical efficacy in a Phase 3 trial.
| Parameter | Value |
|---|---|
| NCT Number | NCT03887455 |
| Phase | Phase 3 |
| Status | Completed |
| Sponsor | Eisai Co., Ltd. |
| Collaborator | Biogen |
| Enrollment | 1,795 patients |
| Duration | 18 months |
| Location | Multiple countries worldwide |
| Drug | Lecanemab (Leqembi) |
| Dosage | 10 mg/kg biweekly IV infusion |
Lecanemab is a monoclonal antibody that selectively binds to and clears soluble amyloid-beta (Aβ) protofibrils, which are believed to be the most toxic form of amyloid plaques in Alzheimer's disease[1:1].
This mechanism differs from earlier anti-amyloid antibodies that primarily targeted monomeric Aβ or showed limited brain penetration.
The trial enrolled patients meeting strict criteria:
| Endpoint | Result | p-value |
|---|---|---|
| Amyloid PET SUVR | -59.1 Centiloids vs baseline | p<0.001 |
| ADAS-Cog14 | -3.8 vs placebo | p<0.001 |
| ADCS-MCI-ADL | +3.5 vs placebo | p<0.001 |
| ADCOMS | -0.44 vs placebo | p<0.001 |
| CSF p-tau181 | Significant reduction | p<0.001 |
| CSF t-tau | Significant reduction | p<0.001 |
The trial demonstrated significant clinical benefit:
Consistent benefits observed across:
| Adverse Event | Lecanemab | Placebo |
|---|---|---|
| ARIA-E (edema) | 12.6% | 1.7% |
| ARIA-H (hemorrhage) | 17.3% | 9.0% |
| Infusion reactions | 20.4% | 4.3% |
Amyloid-related imaging abnormalities (ARIA) are managed through:
Most ARIA cases were asymptomatic or mild; serious events were rare[2].
CLARITY-AD represents a pivotal moment in Alzheimer's disease research as it demonstrates:
The results led to:
For patients with early AD[3]:
The CLARITY-1 (NCT05406091) open-label extension allows patients who completed CLARITY-AD to continue receiving lecanemab, providing:
Research is exploring lecanemab in combination with other therapies:
The DIAN-TU-001 trial is evaluating lecanemab in autosomal dominant AD, while the A4 study continues in preclinical AD.
Eisai has implemented:
van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. The New England Journal of Medicine. 2023. ↩︎ ↩︎
Schilling LP, et al. Amyloid-related imaging abnormalities with lecanemab. Nature Reviews Neurology. 2024. ↩︎
Cummings J, et al. Lecanemab: The new era of Alzheimer's disease treatment. Alzheimer's & Dementia. 2023. ↩︎